Evidence map›Paper›PMID 34817124›Full record

ArticlePharmacology research & perspectives2021

The abrupt pathological deterioration of cisplatin-induced acute kidney injury: Emerging of a critical time point.

Qin Gong, Mulan Wang, Ya Jiang, Chengliang Zha, Dong Yu, Fan Lei, Yingying Luo, Yulin Feng, Shilin Yang, Jun Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization andJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Qin GongSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Mulan WangPharmacology Laboratory, State Key Laboratory of Innovative Drugs and Efficient Energy-saving Pharmaceutical Equipment, Nanchang, China.
Ya JiangSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Chengliang ZhaPharmacology Laboratory, State Key Laboratory of Innovative Drugs and Efficient Energy-saving Pharmaceutical Equipment, Nanchang, China.
Dong YuSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Fan LeiSchool of Life Sciences, Tsinghua University, Beijing, China.
Yingying LuoSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Yulin FengSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Shilin YangSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Jun LiSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.ORCID 0000-0002-2868-9511
Lijun DuSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Jiangxi University of Traditional Chinese Medicine · CNBuchang Pharma (China) · CNTsinghua University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin (CP), an anticancer drug, often causes kidney damage. However, the mechanism of CP-induced acute kidney injury (AKI) is not completely understood. AKI was induced by intravenous injection (i.v.) of cisplatin at doses of 5, 8, and 10 mg/kg. Anemoside B4 (B4) (20 mg/kg, i.m.) and dexamethasone (DXM) (0.5 mg/kg, i.v.) were used for AKI treatment. Biochemical indicators were assessed using an automatic biochemical analyzer, protein expression was analyzed by western blotting, and morphological changes in the kidney were examined by PAS staining. The serum creatinine (Cre) and blood urea nitrogen (BUN) levels did not change significantly in the first 2 days but abruptly increased on the third day after CP injection. The serum albumin (ALB) and total protein (TP) levels decreased in both a time- and dose-dependent manner. The urine protein level increased, the clearing rate of Cre decreased distinctly, and morphologic changes appeared in a dose-dependent manner. The protein expression of p53/caspase-3, NLRP3, IL-6, and TNF-α was obviously upregulated on day 3; concurrently, nephrin and podocin were downregulated. The expression of LC3II and p62 was upregulated significantly as the CP dose increased. B4 and DXM obviously decreased the BUN and Cre levels after 3 or 5 days of treatment. AKI appeared distinctly in a time-dependent manner at 2 to 5 days after the administration of 5 mg/kg CP and in a dose-dependent manner upon the administration of 5, 8, and 10 mg/kg CP. The third day was a significant time point for renal deterioration, and treatment with B4 and DXM within the first 3 days provided significant protection against AKI.

Indexed as

Acute Kidney InjuryAnimalsAntineoplastic AgentsBlood Urea NitrogenCisplatinCreatinineDexamethasoneDose-Response Relationship, DrugHumansMaleRatsRats, Sprague-DawleySaponinsSerum AlbuminTime FactorsUp-Regulationanemoside B4Antineoplastic AgentsCisplatinCreatinineDexamethasoneSaponinsSerum Albuminacute kidney injuryanemoside B4apoptosiscisplatininflammationtherapy

Identifiers

PMID34817124
PMCPMC8611776
OpenAlexW3215055306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.